A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics

Journal of Controlled Release

Volumn 117, Issue 1, 2007, Pages 59-67

  Yi, Yilwoong ^a,b   Yoon, Hye Jeong ^a   Kim, Bong Oh ^a   Shim, Myungseob ^a   Kim, Sun Ok ^a   Hwang, Sung Joo ^b   Seo, Min Hyo ^a  

^a Samyang Corporation   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

Itraconazole; Pharmacokinetics; Polymeric micelle; Solubilization; Stability

Indexed keywords

DRUG DOSAGE; MICELLES; PHARMACOKINETICS; POLYESTERS; SOLUBILITY; TOXICITY;

CLINICAL DOSES; ITRACONAZOLES; POLYMERIC MICELLES; SOLUBILIZATION;

DRUG PRODUCTS;

CYCLODEXTRIN; ITRACONAZOLE; MACROGOL; POLYLACTIC ACID;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOG; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG SOLUBILITY; FEMALE; MALE; MICELLIZATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; DOGS; FEMALE; HEMOLYSIS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; ITRACONAZOLE; LACTIC ACID; LETHAL DOSE 50; MALE; MICELLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33846498531     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.10.001     Document Type: Article

References (30)

1. Strickley R.G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21 (2004) 201-230
2. Keck C.M., and Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 62 (2006) 3-16
3. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3 (2004) 785-796
4. Hong J.-Y., Kim J.-K., Song Y.-K., Park J.-S., and Kim C.-K. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J. Control. Release 110 (2006) 332-338
5. Gaucher G., Dufresne M.-H., Sant V.P., Kang N., Maysinger D., and Leroux J.-C. Block copolymer micelles: preparation, characterization and application in drug delivery. J. Control. Release 109 (2005) 169-188
6. Yi Y., Kim J.H., Kang H.-W., Oh H.S., Kim S.W., and Seo M.H. A polymeric nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier: improvements in cellular uptake and biodistribution. Pharm. Res. 22 (2005) 200-208
7. Kim T.-Y., Kim D.-W., Chung J.-Y., Shin S.G., Kim S.-C., Heo D.S., Kim N.K., and Bang Y.-J. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 10 (2004) 3708-3716
8. Inactive Ingredient Guide (January 1996), Division of Drug Information Resources, Center for Drug Evaluation and Research Office of Management, U.S. Food and Drug Administration, Rockville, MD
9. Anderson J.M., and Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28 (1997) 5-24
10. Li S., and McCarthy S. Further investigations on the hydrolytic degradation of poly (dl-lactide). Biomaterials 20 (1999) 35-44
11. Beule K.D., and Gestel J.V. Pharmacology of itraconazole. Drugs 61 Suppl. 1 (2001) 27-37
12. Boogaerts M.A., Maertens J., Van Der Geest R., Bosly A., Michaux J.-L., Van Hoof A., Cleeren M., Wostenborghs R., and De Beule K. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob. Agents Chemother. 45 (2001) 981-985
13. De Beule K. Itraconazole: pharmacology, clinical experience and future development. Int. J. Antimicrob. Agents 6 (1996) 175-181
14. Groll A.H. Itraconazole-perspectives for the management of invasive aspergillosis. Mycoses 45 Suppl. 3 (2002) 48-55
15. Isoherranen N., Kunze K.L., Allen K.E., Nelson W.L., and Thummel K.E. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos. 32 (2004) 1121-1131
16. Grant S.M., and Clissold S.P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37 (1989) 310-344
17. Heykants J., Van Peer A., Van de Velde V., Van Rooy P., Meuldermans W., Lavrijsen K., Woestenborghs R., Van Cutsem J., and Cauwenbergh G. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32 Suppl. 1 (1989) 67-87
18. Odds F.C., and Bossche H.V. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J. Antimicrob. Chemother. 45 (2000) 371-373
19. Jung J.-Y., Yoo S.D., Lee S.-H., Kim K.-H., Yoon D.-S., and Lee K.-H. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int. J. Pharm. 187 (1999) 209-218
20. Physician's Desk Reference. 59th ed. (2005), Thomson PDR, Montvale, NJ 1757-1766
21. Akkar A., and Müller R.H. Intravenous itraconazole emulsions produced by SolEmuls technology. Eur. J. Pharm. Biopharm. 56 (2003) 29-36
22. Seo M.H., Yi Y., and Yu J.W. Stable Polymeric Micelle-type Drug Composition and Method for the Preparation Thereof. PCT Application PCT/KR01/00802 (May 17, 2001)
23. Kwon G.S., and Okano T. Polymeric micelles as new drug carriers. Adv. Drug Deliv. Rev. 21 (1996) 107-116
24. Carrier A., and Parent J. Liquid chromatographic-mass spectrometric determination of itraconazole and its major metabolite, hydroxy-itraconazole, in dog plasma. J. Chromatogr., B, Biomed. Sci. Appl. 745 (2000) 413-420
25. Yao M., Chen L., and Srinivas N.R. Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. J. Chromatogr., B, Biomed. Sci. Appl. 752 (2001) 9-16
26. Miyake K., Irie T., Arima H., Hirayama F., Uekama K., Hirano M., and Okamoto Y. Characterization of itraconazole/2-hydroxypropyl-β-cyclodextrin inclusion complex in aqueous propylene glycol solution. Int. J. Pharm. 179 (1999) 237-245
27. Peeters J., Neeskens P., Tollenaere J.P., Van Remoortere P., and Brewster M.E. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J. Pharm. Sci. 91 (2002) 1414-1422
28. Janssen Research Foundation, Sporanox IV: Broad Spectrum Antifungal Agent (in D/C Manual) (2002), Janssen Research Foundation, NJ, USA
29. Van Cauteren H., Lampo A., Vandenberghe J., Vanparys P., Coussement W., De Coster R., and Marsboom R. Toxicological profile and safety evaluation of antifungal azole derivatives. Mycoses 32 (1989) 60-66
30. Van Cauteren H., Lampo A., Vandenberghe J., Vanparys P., Coussement W., De Coster R., and Marsboom R. Safety aspects of oral antifungal agents. Br. J. Clin. Pract. 71 (1990) 47-49 (Suppl.)